2 Onvansertib's clinical signal of efficacy and tolerability 2. Generate data from the 1* line RAS-mutated mCRC CRDF-004 trial in mid-2024 Preclinical programs indications Cardiff Oncology is focused on three objectives to create value 1. Lead program: RAS-mut mCRC Generate data from the 1*t line RAS-mutated mCRC CRDF-004 trial in mid-2024 1. – Onvansertib and bevacizumab have independent MOAs reducing tumor vasculature – Data from mCRC study in 135 patients identified resistance mechanisms RAS-mut mCRC Onv ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------|-----------------------------|-------|----------------------------|------------------------------|-------|---------------------|-------|--------------------------------------|-------|------------------------------------------------|-------------------------------------|-------|--------------------------------------| | Balance, January 1, 2023 | Preferred Stock Shares \n61 | $ | Preferre ...

1.00- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------|-------|-------|---------------------------------------|--------------|-----------|-------|---------------------------------|---------------|-------|-----------|-----------------------------------------------|-------|-------|-----------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | robability of Survi©177 | | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) | Delaware | 27-2004382 | | --- | --- | | ...

Certain statements in this presentation are | --- | --- | --- | |----------------------------|---------------------------------|-----------------------------------------------------------------------------------------| | | | | | Our Drug: Onvansertib | WHAT Onvansertib has achieved | Robust clinical proof-of-concept results in Ph 1b/2 KRAS-mutated mCRC trial | | Highly selective and well- | | | | tolerated PLK1-inhibitor | WHERE Cardiff Oncology is going | Onvansertib has opportunity to become part of SOC i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) | Delaware | 27-2004382 | | --- | --- | | (State or other jurisdiction of incorporation or organization) | ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction of ...

The Onvansertib Opportunity Company Overview Forward-looking statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) Delaware 27-2004382 (State or other j ...

The Onvansertib Opportunity Company Overview Forward-Looking Statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...